Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials

• Main Authors: Matthew P. Kosloski (Author), George D. Kalliolias (Author), Christine R. Xu (Author), Sivan Harel (Author), Ching‐Ha Lai (Author), Wenjun Zheng (Author), John D. Davis (Author), Mohamed A. Kamal (Author)
• Format: Book
• Published: Wiley, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Itepekimab is a monoclonal antibody that targets interleukin (IL‐33) and has been shown to reduce airway inflammation and associated tissue damage in preclinical studies. We assessed the safety, tolerability, pharmacokinetics (PKs), and pharmacodynamic profiles of single‐ascending and multi...